SCHEMBL7564523

SCHEMBL7564523

COc1cccc(NC(=O)OCc2cc(N)cc(Nc3c4ccccc4nc4ccccc34)c2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 5/20 0.71
TOP2B Q02880 5/20 0.71
PDE4B Q07343 1/20 0.48
TP53 P04637 2/20 0.48
MAPT P10636 1/20 0.48
POLB P06746 3/20 0.47
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TERT O14746 1/20 0.47
KDR P35968 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KDM1A O60341 1/20 0.45
RAD52 P43351 1/20 0.45
GFER P55789 1/20 0.45
MTNR1B P49286 1/20 0.44
USP2 O75604 1/20 0.44
BLK P51451 1/20 0.44
BTK Q06187 1/20 0.44
TACR3 P29371 1/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7567719 0.93 TOP2A (0.73) TOP2ATOP2BTP53MAPTPOLB
SCHEMBL7234860 0.91 TOP2A (0.56) TOP2ATOP2BPDE4BTP53MAPT
SCHEMBL7570128 0.89 TOP2A (0.74) TOP2ATOP2BPOLBKMT2AMEN1
SCHEMBL3981533 0.89 TOP2A (0.80) TOP2ATOP2BMAPTPOLBKMT2A
SCHEMBL3990019 0.89 TOP2A (0.60) TOP2ATOP2BPDE4BTP53MAPT
SCHEMBL7561273 0.87 TOP2A (0.70) TOP2ATOP2BTP53MAPTPOLB
SCHEMBL7569266 0.87 TOP2A (0.70) TOP2ATOP2BMAPTKMT2AMEN1
SCHEMBL7563689 0.85 TOP2A (0.77) TOP2ATOP2BMAPTPOLBKMT2A
SCHEMBL7562964 0.85 TOP2A (0.71) TOP2ATOP2BMAPTPOLBKMT2A
SCHEMBL6546437 0.85 TOP2A (0.76) TOP2ATOP2BMAPTPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 TOP2A 1105/4885TOP2B 841/4885PDE4B 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.